Autoantibodies in Wilson disease: Impact on clinical course.

Autor: Antczak-Kowalska M; 2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland., Członkowska A; 2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland., Eyileten C; Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharmacology Medical University of Warsaw Warsaw Poland., Palejko A; 2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland., Cudna A; 2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland.; Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharmacology Medical University of Warsaw Warsaw Poland., Wolska M; Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharmacology Medical University of Warsaw Warsaw Poland.; Doctoral School, Medical University of Warsaw Warsaw Poland., Piechal A; 2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland.; Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharmacology Medical University of Warsaw Warsaw Poland., Litwin T; 2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland.
Jazyk: angličtina
Zdroj: JIMD reports [JIMD Rep] 2022 Jul 22; Vol. 63 (5), pp. 508-517. Date of Electronic Publication: 2022 Jul 22 (Print Publication: 2022).
DOI: 10.1002/jmd2.12317
Abstrakt: Symptoms of Wilson disease (WD) vary and additional factors such as autoimmunity may play an important role in WD pathogenesis. The presence of antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies, neuronal surface antibodies, and onconeural antibodies in WD was investigated using standardized indirect immunofluorescence assays and Western Blot analysis. The presence of all studied autoantibodies was higher in WD patients in comparison to healthy subjects, but there was no statistically significant difference in autoantibodies frequency according to disease manifestation. D-penicillamine treatment was associated with a higher presence of ANA than zinc sulfate but without an increase in autoimmune diseases rate.
Competing Interests: The authors declare that they have no conflict of interest.
(© 2022 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.)
Databáze: MEDLINE
Externí odkaz: